COL1A1 polymorphism and neurological complications in pediatric acute lymphoblastic leukemia patients and their associations with altered bone mineral density

Egyptian Journal of Medical Human Genetics

Table 4 Genetic and laboratory characteristics of the patients regarding the detection of fractures as well as neurological complications (during the second assessment)

		Fractures		p value	Neurological complications		p value
		+ve (n = 7)	−ve (n = 93)	p value	+ve (n = 24)	−ve (76)	p value
**COLIA1genotypes**	G/G (n = 55)	0	55 (59%)	0.01*	13 (54%)	42 (55%)	0.68
	G/T (n = 34)	1 (15%)	33 (35%)		8 (33%)	26 (34%)
	T/T (n = 11)	6 (85%)	5 (5%)		3 (12%)	8 (11%)
BMD^LS		− 2.00 ± 0.44	− 1.00 ± 0.11	0.04*	− 2.11 ± 0.41	− 1.10 ± 0.01	0.02*
PTH (ng/l), median (range)		50 (15–59)	49 (12–56)	0.5	48 (20–50)	51 (16–56)	0.9
Vitamin D (nmol/l), median (range)		19 (12–20)	20 (13–35)	0.2	19 (14–35)	20 (15–34)	0.2
OC (ng/ml), median (range)		8 (8–12)	13 (9–20)	0.02*	10 (8–20)	18 (10–19)	0.01*
ALP (U/L), median (range)		45 (45–87)	76 (50–84)	0.03*	50 (45–80)	80 (46–88)	0.01*

*Significant
BMD^LS bone mineral density of lumbar spine, PTH parathormon, OC osteocalcin, ALP alkaline phosphatase